Finance

Lists
Why is 128940 down 3.34%?
Dive Deeper
128940:KRX
Hanmi Pharm Co Ltd
₩433,500.00
-3.34%
(-15,000.00) 1D
Nov 18, 11:28:02 AM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 128940...
Open
₩448,500
High
₩449,000
Low
₩430,000
Mkt. cap
5.55T
Avg. vol.
137.86K
Volume
38.14K
Dividend
0.46%
Quarterly dividend
₩500
Ex-dividend date
Mar 30, 2026
P/E ratio
29.10
52-wk high
₩647,000
52-wk low
₩302,000
EPS
₩14,899
Shares outstanding
12.81M
No. of employees
2K
Open
₩448,500
High
₩449,000
Low
₩430,000
Mkt. cap
5.55T
Avg. vol.
137.86K
Volume
38.14K
Dividend
0.46%
Quarterly dividend
₩500
Ex-dividend date
Mar 30, 2026
P/E ratio
29.10
52-wk high
₩647,000
52-wk low
₩302,000
EPS
₩14,899
Shares outstanding
12.81M
No. of employees
2K
News stories
From web sources and news partners
Profile
Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul. Wikipedia
About Hanmi Pharm Co Ltd
CEO-
Employees2.5K
Founded1973
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
432.96B
392.93B
467.25B
-482.77B
Cost of goods sold
172.48B
175.64B
164.04B
-163.77B
Cost of revenue
172.48B
175.64B
164.04B
-163.77B
Research and development expenses
51.66B
57.12B
52.08B
-109.21B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
125.55B
106.52B
120.03B
-116.85B
Operating expense
205.73B
171.55B
179.72B
-187.58B
Total operating expenses
378.22B
347.19B
343.76B
-351.35B
Operating income
54.74B
45.74B
123.49B
-131.42B
Other non operating income
664.20M
2.62B
-4.88B
-23.24B
EBT including unusual items
58.49B
55.38B
120.14B
-163.22B
EBT excluding unusual items
57.99B
55.26B
119.61B
-162.57B
Income tax expense
4.43B
4.30B
36.06B
-42.06B
Effective tax rate
7.58%
7.76%
30.01%
-
Other operating expenses
-
-
-
54.00B
Net income
48.12B
45.49B
83.31B
-114.80B
Net profit margin
11.11%
11.58%
17.83%
-
Earnings per share
-
-
-
-
Interest and investment income
2.51B
2.62B
2.77B
6.76B
Interest expense
-3.65B
-3.41B
-3.35B
-5.39B
Net interest expenses
-1.14B
-783.67M
-588.23M
1.37B
Depreciation and amortization charges
-
-
-
-
EBITDA
80.03B
70.44B
148.58B
-106.33B
Gain or loss from assets sale
-39.36M
3.68M
40.66M
-
Upcoming events
AI content may include mistakes. Learn more
Google apps